TAGRISSO Patient Savings Program*
*Patients must meet all eligibility requirements to be enrolled in the program.
Helping patients access the care they need
The AstraZeneca Access 360™ program provides personal support to help streamline access and reimbursement for TAGRISSO. Access 360 provides:
Accessing quality and timely molecular testing
TAGRISSO is available for order from the following specialty providers
TAGRISSO is available for purchase from these authorized specialty distributors
Watch expert discussions to help further educate your patients
TAGRISSO Mechanism of Action
See how TAGRISSO inhibits EGFR mutations, a key driver of disease.
Management of Adverse Reactions and Experience With TAGRISSO
Managing patient expectations regarding possible adverse reactions and how to help manage them is a critical aspect of oncology nursing. In this presentation, Beth Sandy, MSN, CRNP, and Blanca Ledezma, MSN, NP, review the most common adverse reactions in the FLAURA study and discuss appropriate symptom management considerations.
11 min 15sec.
TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
You may report side effects related to AstraZeneca products by clicking here.